Thrombopoietin receptor agonists (TPO-RAs) are used as effective alternative treatments in ITP patients unresponsive to first-/second-line therapies. TPO- RAs can also be used to normalize platelet count to safely perform invasive pro- cedures and chemotherapy, in case of malignancies. In few responsive patients, TPO-RAs can be suspended maintaining a sustained response
Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case / Santoro, Cristina; Volpicelli, Paola; Baldacci, Erminia; Ferrara, Grazia; DI ROCCO, Alice; Ferretti, Antonietta; Porrazzo, Marika; Mazzucconi, Maria Gabriella. - In: CLINICAL CASE REPORTS. - ISSN 2050-0904. - ELETTRONICO. - 5:8(2017), pp. 1-4. [10.1002/ccr3.920]
Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case.
Santoro Cristina;VOLPICELLI, PAOLA;Baldacci Erminia;Ferrara Grazia;Di Rocco Alice;Ferretti Antonietta;Porrazzo Marika;Mazzucconi Maria Gabriella
2017
Abstract
Thrombopoietin receptor agonists (TPO-RAs) are used as effective alternative treatments in ITP patients unresponsive to first-/second-line therapies. TPO- RAs can also be used to normalize platelet count to safely perform invasive pro- cedures and chemotherapy, in case of malignancies. In few responsive patients, TPO-RAs can be suspended maintaining a sustained response| File | Dimensione | Formato | |
|---|---|---|---|
|
Santoro_Repeated successful use of eltrombopag_2017.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Altra licenza (allegare)
Dimensione
76.85 kB
Formato
Adobe PDF
|
76.85 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
